Genewity is excited to announce the appointment of Willem-Jan Krebber as Chief Operating Officer (COO), effective September 2024. His appointment is a key step in the company’s transition to advance clinical and commercial production.

The recognition from both regulatory bodies marks an important milestone for the development of i-Thymus.

With i-Thymus, we are not only rebuilding an underestimated organ but also redefining the possibilities for immune recovery.

We are pleased to announce the launch of our newly refined logo and website as part of Genewity's ongoing evolution. This transformation reflects our commitment to innovation, professionalism, and excellence. What is new?

We are thrilled to announce that Bart Bergstein has joined Genewity as our Chief Financial Officer (CFO), effective May 2024. Bart brings to the team a wealth of experience and a proven track record in the financial and life sciences sectors.

We are honored to welcome Sander van Deventer, MD, PhD, a distinguished figure in the life sciences industry, as Strategic Advisor at Genewity. His vast experience in drug development and gene therapy will be an asset to our company.